Effects of immunosuppression on the efficacy of vaccination against Mycoplasma gallisepticum infection in chickens

Arachchige, Sathya N Kulappu; Condello, Anna Kanci; Zhu, Ling; Shil, Pollob; Tivendale, Kelly A.; Underwood, Greg; Noormohammadi, Amir H.; Browning, Glenn F.; Wawegama, Nadeeka K.

doi:10.1016/j.vetmic.2021.109182

Cited by 16 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 collection of blood from the Vena jugularis using Vacutainer. 5 aseptic sampling of milk for bacteriological and single cell count analyses. 6 swab sampling (eye, ear, nose and vagina).…”

Section: Clinical Examinationmentioning

confidence: 99%

“…They are minimalist prokaryotes possessing small genomes with limited coding capacity, yet they can cause considerable damage to the livestock industry [1]. Although vaccines are available for some avian and porcine mycoplasma species, successful vaccines have so far been evasive for most of other species, including ruminant pathogens [2][3][4][5]. One of the major factors hampering vaccine development is…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sheep Infection Trials with ‘Phase-Locked’ Vpma Expression Variants of Mycoplasma agalactiae—Towards Elucidating the Role of a Multigene Family Encoding Variable Surface Lipoproteins in Infection and Disease

et al. 2022

View full text Add to dashboard Cite

The significance of large multigene families causing high-frequency surface variations in mycoplasmas is not well-understood. Previously, VpmaY and VpmaU clonal variants of the Vpma family of lipoproteins of M. agalactiae were compared via experimental sheep infections using the two corresponding ‘Phase-Locked Mutants’. However, nothing is known about the infectivity of the remaining four Vpma expression variants VpmaX, VpmaW, VpmaZ and VpmaV as they were never evaluated in vivo. Here, in vivo infection and disease progression of all six Vpma expressers constituting the Vpma family of type strain PG2 were compared using the corresponding xer1-disrupted PLMs expressing single well-characterized Vpmas. Each of the six PLMs were separately evaluated using the intramammary sheep infection model along with the control phase-variable wildtype strain PG2. Thorough bacteriological, pathological and clinical examinations were performed, including assessment of milk quality, quantity and somatic cell counts. Altogether, the results indicated that the inability to vary the Vpma expression phase does not hamper the initiation of infection leading to mastitis for all six PLMs, except for PLMU, which showed a defect in host colonization and multiplication for the first 24 h p.i. and pathological/bacteriological analysis indicated a higher potential for systemic spread for PLMV and PLMX. This is the first study in which all isogenic expression variants of a large mycoplasma multigene family are tested in the natural host.

show abstract

“…4 collection of blood from the Vena jugularis using Vacutainer. 5 aseptic sampling of milk for bacteriological and single cell count analyses. 6 swab sampling (eye, ear, nose and vagina).…”

Section: Clinical Examinationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Sheep Infection Trials with ‘Phase-Locked’ Vpma Expression Variants of Mycoplasma agalactiae—Towards Elucidating the Role of a Multigene Family Encoding Variable Surface Lipoproteins in Infection and Disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Some U. diversum strains result in immunosuppression by significantly inducing IL-10 expression upon incubation with bovine macrophages [ 73 ]. This increases the susceptibility of the host to other disease-causing pathogens and interferes with the effectiveness of experimental vaccinations against these pathogens [ 73 , 91 ]. rGUDIV-103 stimulated lymphoproliferation and induced iNOS , IL-1β , TNF-α , TLR2 , and TLR4 expression, suggesting that it is a promising target protein for immunobiological studies, as immunostimulation activates the elements capable of fighting infections and cellular and humoral immune responses.…”

Section: Discussionmentioning

confidence: 99%

Heterologous Expression, Purification, and Immunomodulatory Effects of Recombinant Lipoprotein GUDIV-103 Isolated from Ureaplasma diversum

et al. 2022

View full text Add to dashboard Cite

Ureaplasma diversum is a bacterial pathogen that infects cattle and can cause severe inflammation of the genital and reproductive systems. Lipid-associated membrane proteins (LAMPs), including GUDIV-103, are the main virulence factors in this bacterium. In this study, we heterologously expressed recombinant GUDIV-103 (rGUDIV-103) in Escherichia coli, purified it, and evaluated its immunological reactivity and immunomodulatory effects in bovine peripheral blood mononuclear cells (PBMCs). Samples from rabbits inoculated with purified rGUDIV-103 were analysed using indirect enzyme-linked immunosorbent assay and dot blotting to confirm polyclonal antibody production and assess kinetics, respectively. The expression of this lipoprotein in field isolates was confirmed via Western blotting with anti-rGUDIV-103 serum and hydrophobic or hydrophilic proteins from 42 U. diversum strains. Moreover, the antibodies produced against the U. diversum ATCC 49783 strain recognised rGUDIV-103. The mitogenic potential of rGUDIV-103 was evaluated using a lymphoproliferation assay in 5(6)-carboxyfluorescein diacetate succinimidyl ester–labelled bovine PBMCs, where it induced lymphocyte proliferation. Quantitative polymerase chain reaction analysis revealed that the expression of interleukin-1β, toll-like receptor (TLR)-α, TLR2, TLR4, inducible nitric oxide synthase, and caspase-3–encoding genes increased more in rGUDIV-103–treated PBMCs than in untreated cells (p < 0.05). Treating PBMCs with rGUDIV-103 increased nitric oxide and hydrogen peroxide levels. The antigenic and immunogenic properties of rGUDIV-103 suggested its suitability for immunobiological application.

show abstract

“…ADWG was computed for the difference between the starting and final weight divided by the duration of the stage. The gross air sac lesions were scored on a scale of 0 to 4 at necropsy, using a modification of a system described previously 57 . Tracheal tissues were collected from the upper, middle, and lower for histopathologic examination as described previously 58 .…”

Section: Clinical Observation Lesion Score Evaluationmentioning

confidence: 99%

Novel antigenic proteins of Mycoplasma synoviae as potential vaccine candidates

Shi

Han

et al. 2023

Preprint

View full text Add to dashboard Cite

Mycoplasma synoviae (M. synoviae) is a serious avian pathogen causing severe economic losses to chicken and turkey producers worldwide. The currently available live attenuated vaccine and inactivated vaccine on the market elicit only limited protection. The aim of this study was to identify antigenic proteins of M. synoviae as potential subunit vaccine candidates. In immunoproteomics and reverse vaccinology analyses, a total 24 candidate antigens were picked out. Five candidate antigens were selected to evaluate immunogenicity and preliminary protection in a chicken model, including RS01790 (lipoprotein, putative sugar ABC transporter), BMP (BMP family ABC transporter substrate-binding protein), GrpE (nucleotide exchange factor), RS00900 (putative nuclease) and RS00275 (Uncharacterized protein). The results showed that the five antigens had good immunogenicity. They could be localized on the M. synoviae cell membrane and adhere to DF-1 cells using indirect immunofluorescence assay. They induced specific humoral and cellular immune responses. Vaccine efficacy was evaluated by observing weight gain, pathogen load, pathological changes. As a result, the vaccinated chickens revealed significantly higher body weight gain, with lower air sac lesion scores and tracheal mucosal thicknesses. The vaccinated chickens also showed lower M. synoviae loads in throat swabs than nonvaccinated chickens. The protective effect of BMP, GrpE and RS00900 vaccines is better than that of RS01790 and RS00275. In conclusion, our study demonstrates the potential of using subunit vaccine, providing new ideas for the development of M. synoviae vaccines. The vaccine candidates may contribute to the future development of therapeutic strategies to control the spread of M. synoviae worldwide.

show abstract

Effects of immunosuppression on the efficacy of vaccination against Mycoplasma gallisepticum infection in chickens

Cited by 16 publications

References 37 publications

Sheep Infection Trials with ‘Phase-Locked’ Vpma Expression Variants of Mycoplasma agalactiae—Towards Elucidating the Role of a Multigene Family Encoding Variable Surface Lipoproteins in Infection and Disease

Sheep Infection Trials with ‘Phase-Locked’ Vpma Expression Variants of Mycoplasma agalactiae—Towards Elucidating the Role of a Multigene Family Encoding Variable Surface Lipoproteins in Infection and Disease

Heterologous Expression, Purification, and Immunomodulatory Effects of Recombinant Lipoprotein GUDIV-103 Isolated from Ureaplasma diversum

Novel antigenic proteins of Mycoplasma synoviae as potential vaccine candidates

Contact Info

Product

Resources

About